Sakar Healthcare inks pact with Ferring Pharmaceuticals, Bazell Pharma

18 May 2023 Evaluate

Sakar Healthcare has entered into an agreement with the Swiss pharmaceutical major - Ferring Pharmaceuticals and Bazell Pharma LLP for developing the novel drug delivery system (NDDS) for two of the oncology products. Both the products are prescription medicine in segment of oncology- one is androgen biosynthesis inhibitors while the other being first triple-acting, androgen receptor antagonist. Both are extensively used to treat Prostate cancer- while the patented one in liquid sachet is for prostate cancer that has metastasized, the other innovative one in sachet powder is to block testosterone to reach prostate cancer cells. The present worldwide market size for general prostate therapeutics is $12.12 billion, expected to be $21.48 billion by 2030- with a CAGR of 8.4%.

Sakar has initiated for the development of the product and scale up batches at its research-driven API integrated oncology formulation-manufacturing unit at Bavla, near Ahmedabad, Gujarat, India. This back-to-back contract confirms Sakar's capabilities towards product development, process optimization, technology management skills, analytical documentation with cytotoxic products that helped perceive concept towards delivery of products, with exclusive worldwide supply.

Sakar Healthcare is an Indian pharmaceutical company engaged in the manufacturing and marketing of its own pharmaceutical formulations for domestic and international markets.

Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.